OT mobile menu

Search form



To Treat or Not to Treat DCIS

Delineating breast cancer subtypes based on biomarkers. Image © iQoncept/Shutterstock.com 

Recent Content

The US Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq®, Genentech) for treating chemotherapy-refractory, metastatic non-small cell lung cancer (NSCLC), Genentech announced.

When CML patients develop resistance or intolerance to these drugs, transplant may be the only option.

A 46-year-old man is found to have a nasal tumor. After further assessment, a biopsy is performed. What is your diagnosis?

New immunotherapies that target PD-1 are now showing promise for first-line and second-line treatment of metastatic bladder cancer.

Pembrolizumab showed clinical activity against some cases of enzalutamide-refractory metastatic castration-resistant prostate cancer.

Objective tumor responses to pembrolizumab (Keytruda) and nivolumab (Opdivo) are associated with longer times between melanoma diagnosis and treatment.

Adding pembrolizumab (Keytruda) to first-line chemotherapy improves response and survival rates among patients with previously-untreated advanced PD-L1-positive non-small cell lung cancer.

By clicking Accept, you agree to become a member of the UBM Medica Community.